Faeth Therapeutics' PIK-201 Readout to Serve as Major Inflection Point, Oppenheimer Says
MT newswire2026/10/07 16:4512:45 PM EDT, 10/07/2026 (MT Newswires) -- Faeth Therapeutics' (FTH) readout for its PIK-201 phase 2 clinical trial evaluating PIKTOR in endometrial cancer, scheduled in Q4, should be a major inflection point for the company, Oppenheimer said in a Tuesday note. The summary of topline data from the trial is expected by year-end 2026, with evaluations of about 40 patients in endometrial cancer, the brokerage said. Notable data includes overall response rate, landmark survival analyses, and safety profile, Oppenheimer added. PIKTOR may have a bigger opportunity in breast cancer, Oppenheimer said, but added it has a "meaningful market opportunity" in endometrial cancer, which analysts called the "right place" to establish proof of concept. Oppenheimer has an outperform rating and $60 price target on Faeth Therapeutics. Price: 26.09, Change: -0.80, Percent Change: -2.98
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cold wave and rising fuel costs drive electricity prices in northeastern Japan and Tokyo to a four-year high
Japan's spot electricity prices surged to multi-year highs over the weekend.
Google (GOOGL.US) warns that new Australian cybersecurity regulations may cut off minors' access to Gmail
Google stated that a new cybersecurity bill in Australia could prevent minors from using Gmail.
Canaccord Genuity: Lowers Oklo's target price to $66
Crypto prices
More
